Office: 637 Salk Hall

Phone: 412-648-3012

Email: inh3@pitt.edu

orcidLinkedIn

Dr. Hernandez earned her PharmD from the University of Navarra (Spain) in 2013, and she completed her clinical training in the North Middlesex University Hospital and Green Light Pharmacy, both in London (UK). Upon graduation, she was selected as 1 in 48 among thousands of graduates in Spain across all disciplines to receive a “La Caixa” fellowship. This prestigious fellowship supported her PhD studies in Health Services Research and Policy at the University of Pittsburgh Graduate School of Public Health. Completed in 3 years, the research conducted during her PhD yielded 11 first-author peer-reviewed publications and 2 press releases. Published in JAMA Internal Medicine and Stroke, some of these studies were among the first to provide evidence on the real-world outcomes of non-vitamin K antagonist oral anticoagulants after their approval, and were featured in media outlets around the world.

Following her graduation, Hernandez was appointed Assistant Professor at the University of Pittsburgh School of Pharmacy in August 2016. Hernandez’s research program at Pitt Phatmacy is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics and pharmaceutical policy. Specifically, her current research has 3 main areas of focus:
• Real-world use and outcomes of oral anticoagulation therapy in stroke prevention in atrial fibrillation.
• Use of large data sets, advanced data mining techniques and comparative effectiveness research to predict and compare outcomes of antidementia medications.
• Value-based health insurance and health services delivery:
o Comparing pharmaceutical use, spending and outcomes by health services provider and payer.
o Development of value- and outcomes- based pharmaceutical pricing mechanisms.

Hernandez I. Revisiting Outcomes-Based pricing Propositions for the PCSK9 Inhibitor Evolocumab. JAMA Intern Med. In press

Hernandez I, Saba S, Zhang Y. Geographical Variation in the Use of Oral Anticoagulation Therapy in Atrial Fibrillation. Stroke. In press

Hernandez I, Zhang Y. Using Predictive Analytics and Big Data in Optimizing Pharmaceutical Outcomes. Am J Health Syst Pharm. In press

Hernandez I, Zhang Y, Brooks M, Chin P, Saba S. Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke 2017: 48 (1) 159-166

Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of Bleeding with Dabigatran in Atrial Fibrillation. JAMA Intern Med. 2015; 175(1):18-24.

Hernandez I, Zhang Y. Risk of Bleeding with Dabigatran in 2010-2011 Medicare Data. JAMA Intern Med. 2015; 175(7):1245-7

Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drug 2017; 17(1):37-47.

Hernandez I, Smith K, Zhang Y. Cost-Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation at High Risk of Bleeding and Normal Kidney Function. Thromb Res.2017: 123-130

Hernandez I, Zhang Y. Comparing Diffusion of Breakthrough Drug and "Me-Too" Drug in Medicare. J Pharm Innov. 2017; doi: 10.1007/s12247-017-9277

Hernandez I, Zhang Y. Pharmaceutical Use and Spending Trend in Medicare Beneficiaries with Dementia, From 2006 to 2012. Gerontol Geriatr Med. 2017; 3: 2333721417704946

Hernandez I, Zhang Y. Comparing Clinical and Economic Outcomes of Biologic and Conventional Medications in Postmenopausal Women with Osteoporosis. J Eval Clin Pract. 2015; 21(5):840-7

Hernandez I. Time to Reconsider Dabigatran 110 mg in the US. Am J Cardiovasc Drug. 2015; 15(5):307-9

Hernandez, I. Risk Factors for Cardiovascular Events of Anti-dementia Drugs in Alzheimer’s disease patients. J Clin Gerontol Geriatr 2016; 7(3):77-82.


1.“La Caixa” Foundation Fellowship 2013 (1 in 48 selected in Spain in 2013 to receive full tuition and stipend support to pursue Graduate Studies in North America).

2. Excellence Award First of the Pharmacy Class 2013 (University of Navarra).

3. American Heart Association 2016 Fellows Research Day 1st Place Award (Clinical Science Category).

4. PCORI/AHA Challenge Comparative Effectiveness Research and Precision Medicine Approaches for Heart Disease and Stroke Treatment Research and Clinician Challenge Award, December 2016 (1 in 4 selected among 200 submissions).

5. Outstanding Student Award, University of Pittsburgh Graduate School of Public Health, April 2017.

6. Delta Omega National Public Health Honor Society Omicron Chapter Best Doctoral Dissertation Award, April 2017

7. Top 3 Nationwide Pharmacy School 2013 Graduate, Spanish Department of Education, May 2017.